All these findings suggest that rhoifolin may exert its anti-pancreatic cancer activities through signaling pathways of Akt/JNK/ caspase-3 and TGF-β2/SMAD2 (Zheng et al., 2022[205]). The gene discussed is AKT1; the disease is familial pancreatic carcinoma.